Literature DB >> 21161755

Imaging neurotransmitter release by drugs of abuse.

Diana Martinez1, Rajesh Narendran.   

Abstract

Previous studies have shown that imaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers that are specific for brain dopamine receptors can be used to indirectly image the change in the levels of neurotransmitters within the brain. Most of the studies in addiction have focused on dopamine, since the dopamine neurons that project to the striatum have been shown to play a critical role in mediating addictive behavior. These imaging studies have shown that increased extracellular dopamine produced by psychostimulants can be measured with PET and SPECT. However, there are some technical issues associated with imaging changes in dopamine, and these are reviewed in this chapter. Among these are the loss of sensitivity, the time course of dopamine pulse relative to PET and SPECT imaging, and the question of affinity state of the receptor. In addition, animal studies have shown that most drugs of abuse increase extracellular dopamine in the striatum, yet not all produce a change in neurotransmitter that can be measured. As a result, imaging with a psychostimulant has become the preferred method for imaging presynaptic dopamine transmission, and this method has been used in studies of addiction. The results of these studies suggest that cocaine and alcohol addiction are associated with a loss of dopamine transmission, and a number of studies show that this loss correlates with severity of disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21161755     DOI: 10.1007/7854_2009_34

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  16 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

2.  Do reward-processing deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of physiological response to natural rewards and drug cues.

Authors:  Clifford M Cassidy; Mathieu B Brodeur; Martin Lepage; Ashok Malla
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

3.  Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study.

Authors:  Nina B L Urban; Mark Slifstein; Judy L Thompson; Xiaoyan Xu; Ragy R Girgis; Sonia Raheja; Margaret Haney; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2012-01-29       Impact factor: 13.382

4.  Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.

Authors:  Bernard Le Foll; Doris Payer; Patricia Di Ciano; Mihail Guranda; Shinichiro Nakajima; Junchao Tong; Esmaeil Mansouri; Alan A Wilson; Sylvain Houle; Jeff H Meyer; Ariel Graff-Guerrero; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2015-06-19       Impact factor: 7.853

5.  Identifying the molecular basis of inhibitory control deficits in addictions: neuroimaging in non-human primates.

Authors:  Stephanie M Groman; J David Jentsch
Journal:  Curr Opin Neurobiol       Date:  2013-03-22       Impact factor: 6.627

6.  Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene Polymorphisms.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Abdalla Bowirrat; John Giordano; Margaret Madigan; Eric R Braverman; Debmayla Barh; Mary Hauser; Joan Borsten; Thomas Simpatico
Journal:  J Genet Syndr Gene Ther       Date:  2012-04-13

7.  Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Elizabeth Stuller; David Miller; John Giordano; Siobhan Morse; Lee McCormick; William B Downs; Roger L Waite; Debmalya Barh; Dennis Neal; Eric R Braverman; Raquel Lohmann; Joan Borsten; Mary Hauser; David Han; Yijun Liu; Manya Helman; Thomas Simpatico
Journal:  J Addict Res Ther       Date:  2012-11-27

8.  Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study.

Authors:  Patricia Di Ciano; Mihail Guranda; Dina Lagzdins; Rachel F Tyndale; Islam Gamaleddin; Peter Selby; Isabelle Boileau; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2015-10-07       Impact factor: 7.853

9.  Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36.

Authors:  Anders Ettrup; Søren Holm; Martin Hansen; Muhammad Wasim; Martin Andreas Santini; Mikael Palner; Jacob Madsen; Claus Svarer; Jesper Langgaard Kristensen; Gitte Moos Knudsen
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

10.  Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings.

Authors:  Gabriel S Dichter; Cara A Damiano; John A Allen
Journal:  J Neurodev Disord       Date:  2012-07-06       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.